enpp1in1

Enpp-1-IN-1 is an inhibitor of Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1)

Enpp-1-IN-16 is an inhibitor targeting ENPP1 with potential anti-cancer activity.Enpp-1-IN-16 can be used to study insulin resistance in relation to type II diabetes mellitus and various ENPP1-mediated diseases in the chondrocalcinosis and osteoarthritis classes.

NTPDase/NPP1-IN-1 is an inhibitor of ectonucleotidase (NTPDase) and phosphodiesterase-1 (NPP1), with IC50 values of 0.28, 0.92, 0.82, and 0.73 μM for h-NTPDase1, h-NTPDase2, h-NTPDase3, and h-NPP1, respectively. This compound acts as a membrane interaction agent, localizing to the plasma membrane and interacting with cancer cells. NTPDase/NPP1-IN-1 is applicable in breast cancer research.

Enpp-1-IN-14 is a potent inhibitor of Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity.

Enpp-1-IN-10 (compound 1) is a potent inhibitor of Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) with a Ki value of 3.866 μM, suitable for anticancer research [1].

Enpp-1-IN-11 (compound 23) is a highly potent inhibitor of Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1), with a Ki value of 45 nM. It demonstrates excellent stability in human and mouse plasma and exhibits low clearance in both human and mouse liver microsomes, holding promise for anticancer research [1].

Enpp-1-IN-12 (compound 43), an orally active and potent inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) with a K_i of 41 nM, exhibits anti-tumor activity [1].

Enpp-1-IN-13 is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) inhibitor that is able to act on ENPP1 (IC50: 1.29 μM) and ENPP3 (IC50: 20.2 μM), exhibiting anticancer effects.

Compound 88a (Enpp-1-IN-15) is an inhibitor of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp-1), exhibiting a Ki value of 0.00586 nM [1].

Enpp-1-IN-17 (example 274) is a potent inhibitor of ENPP1, with inhibition constants (Ki values) ranging from 100 nM to 1 μM for cGAMP hydrolysis and greater than 1 μM for ATP hydrolysis, demonstrating a selectivity ratio of over 6.4 favoring cGAMP hydrolysis inhibition [1].

Enpp-1-IN-19 (compound 29f) is an orally active inhibitor of ENPP1 that effectively blocks cGAMP hydrolysis with an IC50 of 68 nM. It not only enhances anti-PD-L1 responses and curtails tumor growth in CT26 syngeneic models but also boosts STING-mediated type I interferon responses. Additionally, Enpp-1-IN-19 fosters immune memory and aids in preventing tumor recurrence [1].